About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2025№4
Increasing possibilities for long-term hormonal...

Increasing possibilities for long-term hormonal therapy of endometriosis

DOI
https://dx.doi.org/10.18565/aig.2025.74

Chernukha G.E., Pronina V.A., Sokirka S.P.

1) Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia

The article presents a literature review addressing various aspects of hormonal therapy for endometriosis, with a particular focus on the use of dienogest (DNG). The data of studies demonstrating pleiotropic mechanism of DNG action in endometriosis are presented. A comparative analysis of the literature data on the effects of medical therapy in the management of various manifestations of pain symptoms, reduction of endometrioid foci in different forms of endometriosis, and the prevention of postoperative recurrences was carried out. The effects of therapy on bone mineral density and quality of life of reproductive-aged women and adolescents with endometriosis were also analyzed. The review indicates the necessity for long-term hormonal therapy of endometriosis. The duration of this therapy depends directly on a woman’s compliance; therefore, it is reasonable to develop medications that would be bioequivalent to the original medications, have comparable therapeutic efficacy and high safety profile in combination with economic accessibility for patients. Normetrilla, which contains a micronized form of DNG at a dose of 2 mg, is one of these medications. It has been proven to be bioequivalent to the original medication, with a comparable safety and tolerability profile.  
Conclusion: Normetrilla can be recommended as medical therapy for various forms of endometriosis in women and adolescent girls over 12 years of age after menarche. Further clinical trials are required in order to evaluate the efficacy and safety of the Russian medication Normetrilla in the treatment of endometriosis.

Authors’ contributions: Pronina V.A., Chernukha G.E., Sokirka S.P. – developing the concept of the study; writing the literature review, analysis of the material and preparing the text of the publication; Chernukha G.E. – editing the article.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: This article was prepared with the support of Binnopharm Group JSC. The sponsor has no influence on the selection of material for publication, data analysis and interpretation.
For citation: Chernukha G.E., Pronina V.A., Sokirka S.P. 
Increasing possibilities for  long-term hormonal therapy of endometriosis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (4): 131-137 (in Russian)
 https://dx.doi.org/10.18565/aig.2025.74

Keywords

endometriosis
suppressive hormone therapy
dienogest
Normetrilla
Full text (in Russian)

References

  1. Becker K., Heinemann K., Imthurn B., Marions L., Moehner S., Gerlinger C. et al. Real world data on symptomology and diagnostic approaches of 27,840 women living with endometriosis. Sci. Rep. 2021; 11(1): 20404. https://dx.doi.org/10.1038/s41598-021-99681-3.
  2. Giudice L.C., Kao L.C. Endometriosis. Lancet. 2004; 364(9447): 1789-99. https://dx.doi.org/10.1016/S0140-6736(04)17403-5.
  3. Nirgianakis K., Ma L., McKinnon B., Mueller M.D. Recurrence patterns after surgery in patients with different endometriosis subtypes: a long-term hospital-based cohort study. J. Clin. Med. 2020; 9(2): 496. https://dx.doi.org/10.3390/jcm9020496.
  4. Ceccaroni M., Bounous V.E., Clarizia R., Mautone D., Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur. J. Contracept. Reprod. Health Care. 2019; 24(6): 464-74. https://dx.doi.org/10.1080/13625187.2019.1662391.
  5. Yang X., Bao M., Hang T., Sun W., Liu Y., Yang Y. et al. Status and related factors of postoperative recurrence of ovarian endometriosis: a cross-sectional study of 874 cases. Arch. Gynecol. Obstet. 2023; 307(5): 1495-501. https://dx.doi.org/10.1007/s00404-023-06932-x.
  6. Becker C.M., Bokor A., Heikinheimo O., Horne A., Jansen F., Kiesel L. et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum. Reprod. Open. 2022; 2022(2): hoac009. https://dx.doi.org/10.1093/hropen/hoac009.
  7. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. 2024. (in Russian)].
  8. NICE. Endometriosis: diagnosis and management. NICE guideline. Last updated: 11 November 2024. https://www.nice.org.uk/guidance/ng73.
  9. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Endometriosis: Clinical practice guideline. Australian clinical practice guideline for diagnosis and treatment of endometriosis. Melbourne: RANZCOG; 2021. Available at: https://ranzcog.edu.au/wp-content/uploads/Endometriosis-Clinical-Practice-Guideline.pdf
  10. Saunders P.T.K., Horne A.W. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell. 2021; 184(11): 2807-24. https://dx.doi.org/10.1016/j.cell.2021.04.041.
  11. Becker C.M., Gattrell W.T., Gude K., Singh S.S. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil. Steril. 2017; 108(1): 125-36. https://dx.doi.org/10.1016/j.fertnstert.2017.05.004.
  12. Tang H.C., Lin T.C., Wu M.H., Tsai S.J. Progesterone resistance in endometriosis: A pathophysiological perspective and potential treatment alternatives. Reprod. Med. Biol. 2024; 23(1): e12588. https://dx.doi.org/10.1002/rmb2.12588.
  13. Attia G.R., Zeitoun K., Edwards D., Johns A., Carr B.R., Bulun S.E. Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab. 2000; 85(8): 2897-902. https://dx.doi.org/10.1210/jcem.85.8.6739.
  14. Shimizu Y., Takeuchi T., Mita S., Mizuguchi K., Kiyono T., Inoue M. et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol. Hum. Reprod. 2009; 15(10): 693-701. https://dx.doi.org/10.1093/molehr/gap042.
  15. Lee J., Park H.J., Yi K.W. Dienogest in endometriosis treatment: A narrative literature review. Clin. Exp. Reprod. Med. 2023; 50(4): 223-9. https://dx.doi.org/10.5653/cerm.2023.06128.
  16. Klipping C., Duijkers I., Remmers A., Faustmann T., Zurth C., Klein S. et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J. Clin. Pharmacol. 2012; 52(11): 1704-13. https://dx.doi.org/10.1177/0091270011423664.
  17. Murji A., Biberoğlu K., Leng J., Mueller M.D., Römer T., Vignali M. et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr. Med. Res. Opin. 2020; 36(5): 895-907. https://dx.doi.org/10.1080/03007995.2020.1744120.
  18. Momoeda M., Harada T., Terakawa N., Aso T., Fukunaga M., Hagino H. et al. Long-term use of dienogest for the treatment of endometriosis. J. Obstet. Gynaecol. Res. 2009; 35(6): 1069-76. https://dx.doi.org/10.1111/j.1447-0756.2009.01076.x.
  19. Vahid-Dastjerdi M., Hosseini R., Rodi H., Rastad H., Hosseini L. Comparison of the effectiveness of Dienogest with medroxyprogesterone acetate in the treatment of pelvic pain and recurrence of endometriosis after laparoscopic surgery. Arch. Gynecol. Obstet. 2023; 308(1): 149-55. https://dx.doi.org/10.1007/s00404-022-06898-2.
  20. Ota I., Taniguchi F., Ota Y., Nagata H., Wada I., Nakaso T. et al. A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis. Reprod. Med. Biol. 2021; 20(4): 427-34. https://dx.doi.org/10.1002/rmb2.12408.
  21. Kim H.K., Kim E.S., Park K.S., Lee Y.J., Ha I.H. Current treatments for endometriosis in South Korea: an analysis of nationwide data from 2010 to 2019. Sci. Rep. 2023; 13(1): 9573. https://dx.doi.org/10.1038/s41598-023-36291-1.
  22. Estes S.J., Soliman A.M., Epstein A.J., Bond J.C., Gordon K., Missmer S.A. National trends in inpatient endometriosis admissions: Patients, procedures and outcomes, 2006-2015. PLoS One. 2019; 14(9): e0222889. https://dx.doi.org/10.1371/journal.pone.0222889.
  23. Göhring J., Drewes M., Kalder M., Kostev K. Germany endometriosis pattern changes; Prevalence and therapy over 2010 and 2019 years: a retrospective cross-sectional study. Int. J. Fertil. Steril. 2022; 16(2): 85-9. https://dx.doi.org/10.22074/IJFS.2021.528397.1113.
  24. Ota Y., Andou M., Yanai S., Nakajima S., Fukuda M., Takano M. et al. Long-term administration of dienogest reduces recurrence after excision of endometrioma. Journal of Endometriosis and Pelvic Pain Disorders. 2015; 7(2): 63-7. https://dx.doi.org/10.5301/je.5000219.
  25. Lee S.R., Yi K.W., Song J.Y., Seo S.K., Lee D.Y., Cho S. et al. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reprod. Sci. 2018; 25(3): 341-6. https://dx.doi.org/10.1177/1933719117725820.
  26. Wu H., Liu J.J., Ye S.T., Liu J., Li N. Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2024; 297: 40-9. https://dx.doi.org/10.1016/j.ejogrb.2024.03.032.
  27. Zheng Y., Ma R., Xu H., Wang L., Zhang L., Mao H. et al. Efficacy and safety of different subsequent therapies after fertility preserving surgery for endometriosis: A systematic review and network meta-analysis. Medicine (Baltimore). 2023; 102(31): e34496. https://dx.doi.org/10.1097/MD.0000000000034496.
  28. Zakhari A., Edwards D., Ryu M., Matelski J.J., Bougie O., Murji A. Dienogest and the risk of endometriosis recurrence following surgery: a systematic review and meta-analysis. J. Minim. Invasive Gynecol. 2020; 27(7): 1503-10. https://dx.doi.org/10.1016/j.jmig.2020.05.007.
  29. Ceccaroni M., Clarizia R., Liverani S., Donati A., Ceccarello M., Manzone M. et al. Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. Gynecol. Endocrinol. 2021; 37(10):930-3. https://dx.doi.org/10.1080/09513590.2021.1929151.
  30. Barra F., Scala C., Leone Roberti Maggiore U., Ferrero S. Long-term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis. J. Clin. Med. 2020; 9(1):154. https://dx.doi.org/10.3390/jcm9010154.
  31. Гусев Д.В., Прилуцкая В.Ю., Чернуха Г.Е. Рецидивы эндометриоидных кист яичников и возможные пути их снижения. Гинекология. 2020; 22(3):34-8. [Gusev D.V., Prilutskaya V.Yu., Chernukha G.E. Reccurence of endometrioid ovarian cysts and possible ways to its reduce. Gynecology. 2020; 22(3): 34-8. (in Russian)]. https://dx.doi.org/10.26442/20795696.2020.3.200144.
  32. Ebert A.D., Dong L., Merz M., Kirsch B., Francuski M., Böttcher B. et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis - VISanne study to assess safety in ADOlescents (VISADO Study). J. Pediatr. Adolesc. Gynecol. 2017; 30(5): 560-7. https://dx.doi.org/10.1016/j.jpag.2017.01.014.
  33. Mehdizadeh Kashi A., Niakan G., Ebrahimpour M., Allahqoli L., Hassanlouei B., Gitas G. et al. A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis. Int. J. Gynaecol. Obstet. 2022; 156(1): 124-32. https://dx.doi.org/10.1002/ijgo.13677.
  34. Choi S.H., Kim S.E., Lim H.H., Lee D.Y., Choi D. Efficacy of post-operative medication to prevent recurrence of endometrioma: cyclic oral contraceptive (OC) after gonadotropin-releasing hormone (GnRH) agonist versus dienogest. J. Korean Med. Sci. 2022; 37(26): e207. https://dx.doi.org/10.3346/jkms.2022.37.e207.
  35. Piacenti I., Viscardi M.F., Masciullo L., Sangiuliano C., Scaramuzzino S., Piccioni M.G. et al. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice? Gynecol. Endocrinol. 2021; 37(5): 471-5. https://dx.doi.org/10.1080/09513590.2021.1892632.
  36. Angioni S., Pontis A., Malune M.E., Cela V., Luisi S., Litta P. et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol. Endocrinol. 2020; 36(1): 84-6. https://dx.doi.org/10.1080/09513590.2019.1640674.
  37. Wu Y., Wang H., Chen S., Lin Y., Xie X., Zhong G. et al. Migraine is more prevalent in advanced-stage endometriosis, especially when co-occuring with adenomoysis. Front. Endocrinol. (Lausanne). 2022; 12: 814474. https://dx.doi.org/10.3389/fendo.2021.814474.
  38. Merki-Feld G.S., Caveng N., Speiermann G., MacGregor E.A. Migraine start, course and features over the cycle of combined hormonal contraceptive users with menstrual migraine - temporal relation to bleeding and hormone withdrawal: a prospective diary-based study. J. Headache Pain. 2020; 21(1): 81. https://dx.doi.org/10.1186/s10194-020-01150-1.
  39. Bourdon M., Maignien C., Giraudet G., Estrade J.P., Indersie E., Solignac C. et al. Investigating the medical journey of endometriosis-affected women: Results from a cross-sectional web-based survey (EndoVie) on 1,557 French women. J. Gynecol. Obstet. Hum. Reprod. 2024; 53(2): 102708. https://dx.doi.org/10.1016/j.jogoh.2023.102708.
  40. Heinemann K., Imthurn B., Marions L., Gerlinger C., Becker K., Moehner S. et al. Safety of dienogest and other hormonal treatments for endometriosis in real-world clinical practice (VIPOS): a large noninterventional study. Adv. Ther. 2020; 37(5): 2528-37. https://dx.doi.org/10.1007/s12325-020-01331-z.
  41. Maiorana A., Maranto M., Restivo V., Gerfo D.L., Minneci G., Mercurio A. et al. Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis. Arch. Gynecol. Obstet. 2024; 309(2): 589-97. https://dx.doi.org/10.1007/s00404-023-07271-7.
  42. Techatraisak K., Hestiantoro A., Soon R., Banal-Silao M.J., Kim M.R., Seong S.J. et al. Impact of long-term dienogest therapy on quality of life in Asian women with endometriosis: the prospective non-interventional study ENVISIOeN. Reprod. Sci. 2022; 29(4): 1157-69. https://dx.doi.org/10.1007/s43032-021-00787-w.
  43. Общая характеристика лекарственного препарата «Норметрилла» 2 мг, таблетки. ЛП-№(008252)-(РГ-RU)-241224. Доступно по: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=65b239f6fb44f16274c247bc&codeId=P.MM.01 [Summary of product characteristics of Normetrilla 2 mg, tablets. LP-№(008252)-(RG-RU)-241224. Available at: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=65b239f6fb44f16274c247bc&codeId=P.MM.01 (in Russian)].
  44. Общая характеристика лекарственного препарата «Визанна» 2 мг, таблетки. Соответствует экспертному отчету от 05.12.2022 №28136 (последовательность 0002). Доступно по: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=66ab80e130dcf88d7dd89cd5&codeId=P.MM.01 [Summary of product characteristics of Vizanna 2 mg, tablets. Corresponds to the Expert Report dated 05.12.2022 No. 28136 (sequence 0002). Available at: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=66ab80e130dcf88d7dd89cd5&codeId=P.MM.01 (in Russian)].
  45. Отчет о клиническом исследовании препарата диеногеста 2 мг, таблетки. Проект № 2011-2559, 2011 г. (информация может быть предоставлена по запросу на адрес info@binnopharmgroup.ru). [Clinical study report for dienogest 2 mg tablet. Project No. 2011-2559, 2011 (information can be provided upon request at info@binnopharmgroup.ru) (in Russian)].
  46. Отчет «Тест сравнительной кинетики растворения лекарственных препаратов диеногеста и препарата сравнения «Визанна»» (информация может быть предоставлена по запросу на адрес info@binnopharmgroup.ru). [Report «Test of comparative dissolution kinetics of dienogest medicinal products and Visanna reference product» (information may be provided upon request at info@binnopharmgroup.ru) (in Russian)].

Received 13.03.2025

Accepted 07.04.2025

About the Authors

Galina E. Chernukha, Dr. Med. Sci., Professor, Chief Researcher at the Department of Gynecological Endocrinology, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4, +7(985)999-60-00, c-galina1@yandex.ru, https://orcid.org/0000-0002-9065-5689
Veronika A. Pronina, PhD, obstetrician-gynecologist at the Department of Gynecological Endocrinology, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
117997, Russia, Moscow, Ac. Oparin str., 4, +7(916)025-86-26, ver22595@yandex.ru, https://orcid.org/0000-0003-4566-4065
Sofia P. Sokirka, Student of the N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
(Sechenov University), 119991, Russia, Moscow, Trubetskaya str., 8-2, +7(985)724-42-24, shevtsova.sonya9900@yandex.ru
Corresponding author: Veronika A. Pronina, ver22595@yandex.ru

Similar Articles

№7 / 2024
Ponomareva T.A., Altukhova O.B., Ponomarenko I.V., Churnosov M.I.
Novel concepts in the pathogenesis and risk factors of endometriosis
№7 / 2024
Managadze I.D., Nesterova A.A., Levakov S.A.
Modern approaches to complex patient-focused therapy of endometriosis as a psychosomatic pathology of social significance
№3 / 2025
Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Lobacheva Yu.I., Smagina Yu.A.
Characteristics of Buserelin-depo use in the treatment for comorbid pathologies of reproductive organs
№2 / 2025
Levakov S.A., Gromova T.A., Titova N.R., Aslanova M.S., Managadze I.J.
Psycho-emotional status of patients with endometriosis and chronic pelvic pain: relationship analysis and prospects for further research
№11 / 2024
Menzhinskaya I.V., Pavlovich S.V., Melkumyan A.G., Chuprynin V.D.
A profile of autoantibodies to steroid hormones and steroidogenic enzymes in women with endometriosis
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.